Dutch RNA therapeutics SME with H2020 expertise in endo-lysosomal biology, intracellular RNA transport, and cardiovascular metabolic disease.
InteRNA Technologies is a Dutch biotech SME based in Nijmegen that works in RNA-based therapeutics, bringing industry expertise to the academic RNA biology community through EU training networks. Their H2020 participation spans two consecutive MSCA programmes: one focused on circular RNA biogenesis and one on the endo-lysosomal machinery that determines whether RNA molecules reach their cellular targets or are degraded. The endo-lysosomal focus is scientifically strategic — endosomal escape is one of the central unsolved problems in RNA drug delivery, and their engagement with this biology connects directly to how RNA medicines (including microRNA mimics and inhibitors) behave inside cells. As a private company participating in academic consortia, they contribute translational context and industry mentorship to early-career researchers while gaining scientific access to foundational cell biology relevant to their therapeutic pipeline.
Both H2020 projects (circRTrain and EndoConnect) engage with RNA molecular biology — from circular RNA biogenesis to the intracellular transport mechanisms directly relevant to RNA drug delivery.
EndoConnect (2021–2025) focuses on the molecular regulation of endo-lysosomal processes, with explicit keywords including endosomes, lysosomes, intracellular transport, and organelles.
EndoConnect keywords include cardiovascular disease, cholesterol, metabolism, liver, and adipose tissue — disease-relevant application areas tied to their endo-lysosomal research.
InteRNA participated in two consecutive MSCA-ITN training networks (circRTrain and EndoConnect), providing an industry perspective and translational mentorship to academic early-career researchers.
In the first project (circRTrain, 2017–2021), InteRNA's scientific contribution is not characterized by available keywords, suggesting an associative or third-party role at the periphery of the consortium rather than a central research function. By the second project (EndoConnect, 2021–2025), their engagement sharpens considerably around endo-lysosomal biology, lipid and cholesterol metabolism, and disease-relevant tissues including liver and adipose tissue. This shift closely mirrors a broader trend in the RNA therapeutics field: as RNA drug chemistry matured, the field's central challenge moved to intracellular delivery and endosomal escape, and InteRNA's project choices track that evolution directly.
InteRNA is deepening its scientific engagement with endo-lysosomal cell biology and lipid metabolism — exactly the intracellular mechanisms that govern RNA drug delivery efficiency — which makes them an increasingly relevant partner for projects combining RNA medicine with lipid nanoparticle or targeted intracellular delivery research.
InteRNA has never coordinated an H2020 project, always joining as a partner or participant in large MSCA training networks — a pattern typical of SMEs that contribute specialized industry expertise to academic consortia without setting the scientific agenda. Their 21 consortium partners across 9 countries, accumulated across just two ITN-type networks, reflects the broad multi-institutional structure of MSCA training grants rather than a wide independent partnering strategy. Working with them likely means engaging them as an industry contributor in a training or translational research context, rather than as a project driver.
InteRNA has worked with 21 distinct consortium partners across 9 countries, entirely through MSCA training networks where partner diversity is built into the funding scheme. Their network is shaped by the European academic RNA biology community rather than by industry clusters or national partnerships.
InteRNA occupies a specific niche in the Dutch biotech landscape as an RNA therapeutics SME with direct scientific engagement in endo-lysosomal biology — a field that sits at the heart of RNA drug delivery challenges. Most industry partners in MSCA networks contribute company access and career training; InteRNA goes further by engaging substantively with the intracellular cell biology underpinning their own therapeutic work. For consortium builders in RNA medicine, gene therapy delivery, or lipid nanoparticle research, they offer a compact but scientifically engaged industry partner with relevant disease focus areas including cardiovascular disease and liver biology.
